TickerFacts.

Allurion Technologies, Inc. (ALUR): Cost of Revenue

Annual figures by period end, from SEC filings.

$5.66M
Year ended 2025-12-31
$5.96M
Trailing 12 months to 2026-03-31
-25.1%
3-year compound annual growth
$13.48M2022-12-31: $13.48M2023-12-31: $11.97M2024-12-31: $10.61M2025-12-31: $5.66M$5.66M
2022-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$5.66M-46.6%2026-03-30, From 2025-01-01
2024-12-31$10.61M-11.4%2026-03-30, From 2024-01-01
2023-12-31$11.97M-11.2%2025-08-28, From 2023-01-01
2022-12-31$13.48Mn/a2025-08-28, From 2022-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Allurion Technologies, Inc. (ALUR)2025-12-31$5.66M-46.6%
Biotricity Inc. (BTCY)2026-03-31$3.05M-5.5%
Profound Medical Corp. (PROF)2025-12-31$4.71M+29.2%
Vivos Therapeutics, Inc. (VVOS)2025-12-31$6.90M+14.8%
Nephros Inc (NEPH)2025-12-31$7.16M+31.7%
Sonoma Pharmaceuticals, Inc. (SNOA)2026-03-31$12.11M+37.3%
Spectral AI, Inc. (MDAI)2025-12-31$10.72M-34.2%
Nexgel, Inc. (NXGL)2025-12-31$6.91M+16.4%
DarioHealth Corp. (DRIO)2025-12-31$9.69M-29.6%

Compare ALUR, BTCY, PROF, VVOS side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗